Læknablaðið - 15.11.2000, Síða 51

FRÆÐIGREINAR / ERFÐARÁÐGJÖF
Heimildir
1. Tryggvadóttir L, Tulinius H, Robertsson J McD. Familial and
sporadic breast cancer cases in Iceland: A comparison related
to ABO blood groups and risk of bilateral breast cancer. Int J
Cancer 1988; 42:499-501.
2. Eyfjörd JE, Thorlacius S. Genetic changes in breast
carcinomas in an Icelandic population. Pharmacognetics 1992;
2: 309-16.
3. Sneider NR, Williams WR, Chaganti SK. Genetic
epidemology of familial aggregation of cancer. Adv Cancer
Res 1986; 47:1-32.
4. Birch JM. Familial cancer syndromes and clusters. Br Med
Bull 1994; 50: 624-39.
5. Tulinius H, Sigvaldason H, Olafsdottir G, Tryggvadottir L.
Epidemology of breast cancer in families in Iceland. J Med
Genet 1992; 29:158-64.
6. Ford D, Easton DF. The genetics of breast and ovarian cancers.
Br J Cancer 1995; 72: 805-12.
7. Rahman N, Stratton MR. The Genetics of breast cancer
susceptability. Annu Rev Genet 1998; 32: 95-121.
8. Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G,
Jonasson JG, Tryggvadottir L, et al. Study of a single BRCA2
mutation with high carrier frequency in a small population.
Am J Hum Genet 1997; 60:1079-84.
9. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M,
McAdams M, et al. The risk of cancer associated with specific
mutations of BRCAl and BRCA2 among Ashkenazi Jews. N
Engl J Med 1997; 336:1401-8.
10. Whittemore AS, Gong G, Itnyre J. Prevelence and
contribution of BRCAl mutations in breast cancer and
ovarian cancer: results from the U.S. population-based case-
control study of ovarian cancer. Am J Hum Genet 1997; 60:
469-504.
11. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis
- Effects of prophylactic mastectomy and ophorectomy of life
expecting among women with BRCAl or BRCA2 mutations.
N Engl J Med 1997; 336:1465-71.
12. Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH,
Sigvaldason H, Tryggvadottir L, et al. Population-based study
of risk of breast cancer in carriers of BRCA2 mutation. The
Lancet 1998; 352:1337-9.
13. Baum A, Friedman AL, Zakowski SG. Stress and genetic
testing for disease risk. Health Psychology 1997; 16:8-19.
14. Burke W, Daly M, Garber J, Botkin J, Kahn M, Lynch P, et al.
Recommendations for follow-up care of individuals with an
inherited predisposition to cancer. JAMA 1997; 277: 997-1003.
15. Lerman C, Croyle R. Emotional and behavioral responses to
genetic testing for susceptibility to cancer. Oncology 1996;10:
191-5.
16. Lerman C, Seay J, Balshem A, Audrian J. Interest in genetic
testing among fírst-degree relatives of breast cancer patients.
Am J Med Genet 1995; 57: 358-92.
17. Tambor ES, Rimer BK, Strigo TS. Genetic testing for breast
cancer susceptibility: awareness and interest among women in
the general population. Am J Med Genet 1997; 68: 43-9.
18. Lerman C, Daly M, Masny A, Balshem AM. Attitudes about
genetic testing for breast-ovarian cancer susceptibility. J Clin
Oncol 1994; 12: 843-50.
19. Struewing JP, Lerman C, Kase RG, Gianbarresi TR, Tucker
MA. Anticipated uptake and impact of genetic testing in
hereditary breast and ovarian cancer families. Cancer
Epidemiol Biomarkers Prev 1995; 4:169-73.
20. Lerman C, Narod S, Schulman K, Hughes C, Gomez-
Caminero A, Bonney G, et al. BRCAl testing in families with
hereditary breast-ovarian cancer. JAMA 1996; 275:1885-92.
21. Lerman C, Schwartz M. Adherence and psychological
adjustment among women at high risk for breast cancer.
Breast Cancer Research and Treatment 1993; 28: 145-55.
22. Lerman C, Croyle R. Psychological issues in genetic testing for
breast cancer susceptibility. Arch Intern Med 1994; 154: 609-
16.
23. Croyle R, Lerman C. Interest in genetic testing for colon
cancer susceptibility: cognitive and emotional correlates.
Prevent Med 1993; 22: 284-92.
24. Lerman C, Daly M, Sands C, Balshem AM, Lustbader E,
Heggan T, et al. Mammography adherence and psychological
distress among women at risk for breast cancer. J Nat Cancer
Inst 1993; 85:1074-80.
25. Stefanek ME, Wilcon P. First degree relatives of breast cancer
patients: screening practices and provision of risk information.
Cancer Detect and Prevent 1991; 15: 379-84.
26. McCaul KD, Schroeder DM, Reid PA. Breast cancer worry
and screening: some prospective data. Health Psychology
1996:15: 430-33.
27. Haily BJ. Family history of breast cancer and screening
behavior: an inverted U-shaped curve? Med Hypotheses 1991;
36: 397-403.
28. Valdimarsdottir HB, Bovbjerg D, Brown K, Jacobsen P.
Schwartz MD, Bleiker E, et al. Cancer-specific distress is
related to women's decisions to undergo BRCAl testing.
Cancer Res Thera 1998; 28:1-3.
29. Jacobsen PB, Valdimarsdottir HB, Brown KL, Offit K.
Decision-making about genetic testing among women at
familial risk for breast cancer. Psychosom Med 1997; 59: 459-
66.
30. Horowitz M, Wilner N, Alverez W. Impact of Event Scale: a
measure of subjective stress. Psychosom Med 1979; 41:209-18.
31. Fries, MH, Murphy KM, Flanagan J, Nunes M, McCIellan D,
Barholomew D. Patient indications for mutation testing after
referral for genetic counseling for breast/ovarian cancer. Am J
Hum Genet 1997; 61: A384.
32. Carter CL, Hailey BJ. Psychological issues in genetic testing
for breast cancer. Women & Health 1999; 28:73-91.
33. Claus EB, Risch N, Thompson WD. Genetic analysis of breast
cancer in the cancer and steroid hormone study. Am J Hum
Genet 1991; 48:323-42.
34. King MC, Rowell S, Love SM. Inherited breast and ovarian
cancer: what are the risks? What are the choices? JAMA 1993;
269:1975-80.
35. Lerman C, Lustbader E, Rimer B, Daly M, Miller S, Sands C,
et al. Effects of individualized breast cancer risk counselling: a
randomized trial. J Natl Cancer Inst 1995; 87: 286-92.
Fræðigreinar íslenskra lækna í
erlendum tímaritum
Getiö er fræðigreina. Sendið heiti grcinar, nöfn höfunda og birtingarstað.
Miðað er við greinar sem birst hafa á yfirstandandi og síðasta ári. Til
glöggvunar verður íslcnskra höfunda getið með fornafni þótt svo hafi ekki
verið við birtingu.
* Ehnebom J, Björquist P, Ólöf Sigurðardóttir, Deinum J.
Characterization ofthe interaction of plasminogen activator inhibitor type 1 with
vitronectin by surface plasmon resonance. Fibinolysis & Proteolysis 2000; 14:
47-57.
Læknablaðið 2000/86 777